Exendin-9,39 and Satiety After Bariatric Surgery

Mayo Clinic

Status: Completed

Conditions: Obesity

Treatments: Drug: Exendin-9,39; Drug: Saline

Study type: Interventional

Funder types: Other

Identifiers

NCT02779075

16-001973

Details and patient eligibility

About

The overall aim of the application is to determine the contribution of the elevated incretin hormone concentrations seen after certain types of bariatric surgery to the regulation of food intake and satiety.

Full description

Both Sleeve Gastrectomy (SG) and Roux-en-Y Gastric Bypass (RYGB) increase GLP-1 concentrations, although this is of lesser magnitude in SG compared to RYGB. Data suggests that endogenous GLP-1 is at least partially responsible for reducing free-choice caloric intake after RYGB, providing a mechanism underlying differences between procedures. Inhibition of GLP-1 action with Exendin-9,39 after RYGB accelerates gastric emptying. These observations suggest that factors other than anatomy regulate the upper gastrointestinal response to food ingestion. It is therefore reasonable to consider that the postprandial rise in GLP-1 might affect feeding behavior after RYGB, and to a lesser extent SG, where the increase in GLP-1 is less marked.

Enrollment: 29 patients

Sex: All

Ages: 20 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Undergone either sleeve gastrectomy or Roux-en-Y Gastric Bypass surgery within prior 2 years
• Healthy, with no active systemic illness

Exclusion criteria

• Pregnancy
• Functional or organic bowel symptoms
• Systemic illness
• Diabetes
• Bariatric surgery > 2 years

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

29 participants in 2 patient groups, including a placebo group

Saline

Placebo Comparator group

Description:

0.9% NaCL (saline) intravenously for 6 hours.

Treatment:

Drug: Saline

Exendin-9,39

Active Comparator group

Description:

Exendin-9,39 intravenously for 6 hours.

Treatment:

Drug: Exendin-9,39